New approaches to measuring anthelminthic drug efficacy: Parasitological responses of childhood schistosome infections to treatment with praziquantel

Parasites and Vectors

Volumn 9, Issue 1, 2016, Pages

  Walker, Martin ^a   Mabud, Tarub S ^a,o   Olliaro, Piero L ^b,c   Coulibaly, Jean T ^d,e,f,g   King, Charles H ^h,i   Raso, Giovanna ^d,e   Scherrer, Alexandra U ^j   Stothard, J Russell ^k   Sousa Figueiredo, José Carlos ^l,m   Stete, Katarina ⁿ   Utzinger, Jürg ^d,e   Basáñez, Maria Gloria ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

^g CENTRE SUISSE DE RECHERCHES SCIENTIFIQUES EN CÔTE D'IVOIRE   (Côte d’Ivoire)

^h CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF GEORGIA   (United States)

^j UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^k LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^l Provincial Hospital   (Angola)

^m DEPARTMENT OF LIFE SCIENCES   (United Kingdom)

ⁿ UNIVERSITY OF FREIBURG   (Germany)

^o STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Anthelminthic drug efficacy; Bayesian methods; Conditional models; Egg reduction rate; Marginal models; Praziquantel; Schistosomiasis

Indexed keywords

PRAZIQUANTEL; ANTHELMINTIC AGENT;

ADOLESCENT; AFRICAN; ANALYTIC METHOD; ARTICLE; BAYES THEOREM; CHILD; CLINICAL EFFECTIVENESS; CONDITIONAL MODEL; CONTROLLED STUDY; FEMALE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MARGINAL MODEL; NONHUMAN; ONSET AGE; PARASITE CLEARANCE; PARASITE CONTROL; POPULATION DISTRIBUTION; POPULATION RESEARCH; PREVENTIVE MEDICINE; SCHISTOSOMA HAEMATOBIUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS HAEMATOBIA; SCHISTOSOMIASIS MANSONI; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE; AFRICA; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; FECES; HELMINTHIASIS; OVUM; PARASITOLOGY; PRESCHOOL CHILD; SCHISTOSOMATIDAE; SCHISTOSOMIASIS; STATISTICAL MODEL;

ADOLESCENT; AFRICA; ANIMALS; ANTHELMINTICS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; FECES; FEMALE; HELMINTHIASIS; HUMANS; MALE; MODELS, STATISTICAL; OVUM; PRAZIQUANTEL; SCHISTOSOMATIDAE; SCHISTOSOMIASIS; TREATMENT OUTCOME;

EID: 84956918446     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/s13071-016-1312-0     Document Type: Article

References (64)

1. Reddy M, Gill SS, Kalkar SR, Wu W, Anderson PJ, Rochon PA. Oral drug therapy for multiple neglected tropical diseases: a systematic review. JAMA. 2007;298:1911-24.
2. World Health Organization. Accelerating Work to Overcome the Global Impact of Neglected Tropical Diseases: A Roadmap for Implementation. Geneva: World Health Organization; 2012.
3. Hotez PJ, Alvarado M, Basáñez MG, Bolliger I, Bourne R, Boussinesq M, et al. The global burden of disease study 2010: interpretation and implication for the neglected tropical diseases. PLoS Negl Trop Dis. 2014;8, e2865.
4. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global burden of disease study 2010. Lancet. 2012;380:2197-223.
5. World Health Organization. Preventative Chemotherapy in Human Helminthiasis: Coordinated use of Anthelmintic Drugs in Control Interventions: A Manual for Health Professionals and Programme Managers. Geneva: World Health Organization; 2006. p. 1-62.
6. Bockarie MJ, Kelly-Hope LA, Rebollo M, Molyneux DH. Preventive chemotherapy as a strategy for elimination of neglected tropical parasitic diseases: endgame challenges. Phil Trans R Soc B. 2013;368:20120144.
7. Utzinger J, Becker SL, Knopp S, Blum J, Neumayr AL, Keiser J, et al. Neglected tropical diseases: diagnosis, clinical management, treatment and control. Swiss Med Wkly. 2012;142:w13727.
8. Wang W, Wang L, Liang Y. Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res. 2012;111:1871-7.
9. Albonico M, Engels D, Savioli L. Monitoring drug efficacy and early detection of drug resistance in human soil-transmitted nematodes: a pressing public health agenda. Int J Parasitol. 2004;34:1205-10.
10. Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming F, Zhang Y, et al. The schistosomiasis control initiative (SCI): rationale, development and implementation from 2002-2008. Parasitology. 2009;136:1719-30.
11. Basáñez MG, McCarthy JS, French MD, Yang GJ, Walker M, Gambhir M, et al. A research agenda for helminth diseases of humans: modelling for control and elimination. PLoS Negl Trop Dis. 2012;6:e1548.
12. Webster JP, Molyneux DH, Hotez PJ, Fenwick A. The contribution of mass drug administration to global health: past, present and future. Phil Trans R Soc B. 2014;369:2013034.
13. World Health Organization. Assessing the Efficacy of Anthelminthic Drugs Against Schistosomiasis and Soil-Transmitted Helminthiases. Geneva: World Health Organization; 2013.
14. Olliaro PL, Vaillant M, Diawara A, Coulibaly JT, Garba A, Keiser J, et al. Toward measuring Schistosoma response to praziquantel treatment with appropriate descriptors of egg excretion. PLoS Negl Trop Dis. 2015;9:e0003821.
15. Cabaret J, Berrag B. Faecal egg count reduction test for assessing anthelmintic efficacy: average versus individually based estimations. Vet Parasitol. 2004;121:105-13.
16. Walker M, Churcher TS, Basáñez MG. Models for measuring anthelmintic drug efficacy for parasitologists. Trends Parasitol. 2014;30:528-37.
17. Diggle PJ, Heagerty PJ, Liang KY, Zeger SL. Analysis of Longitudinal Data. Oxford: Oxford University Press; 2002.
18. Subramanian SV, O'Malley AJ. Modeling neighborhood effects: the futility of comparing mixed and marginal approaches. Epidemiol. 2010;21:475-8.
19. Olds GR, King C, Hewlett J, Olveda R, Wu G, Ouma J, et al. Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths. J Infect Dis. 1999;179:996-1003.
20. Coulibaly JT, Fürst T, Silué KD, Knopp S, Hauri D, Ouattara M, et al. Intestinal parasitic infections in schoolchildren in different settings of Côte d'Ivoire: effect of diagnostic approach and implications for control. Parasit Vectors. 2012;5:135.
21. Stete K, Krauth SJ, Coulibaly JT, Knopp S, Hattendorf J, Müller I, et al. Dynamics of Schistosoma haematobium egg output and associated infection parameters following treatment with praziquantel in school-aged children. Parasit Vectors. 2012;5:298.
22. Utzinger J, N'Goran EK, N'dri A, Lengeler C, Tanner M. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Int Health. 2000;5:771-8.
23. Utzinger J, Booth M, N'Goran EK, Müller I, Tanner M, Lengeler C. Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of Schistosoma mansoni before and after treatment with praziquantel. Parasitology. 2001;122:537-44.
24. Raso G, N'Goran EK, Toty A, Luginbühl A, Adjoua CA, Tian-Bi NT, et al. Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western Côte d'Ivoire. Trans R Soc Trop Med Hyg. 2004;98:18-27.
25. Scherrer AU, Sjöberg MK, Allangba A, Traoré M, Lohourignon LK, Tschannen AB, et al. Sequential analysis of helminth egg output in human stool samples following albendazole and praziquantel administration. Acta Trop. 2009;109:226-31.
26. Sousa-Figueiredo JC, Betson M, Atuhaire A, Arinaitwe M, Navaratnam AM, Kabatereine NB, et al. Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. PLoS Negl Trop Dis. 2012;6, e1864.
27. Lahiri SN. Resampling Methods for Dependent Data. New York: Springer; 2003.
28. R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2015.
29. Halekoh U, Højsgaard S, Yan J. The R package geepack for generalized estimating equations. J Stat Softw. 2006;15:1-11.
30. Bates D, Maechler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67:1-48.
31. Hadfield JD. MCMC methods for multi-response generalized linear mixed models: the MCMCglmm R package. J Stat Softw. 2010;33:1-22.
32. Gelman AC, Stern J, Rubin DB. Bayesian Data Analysis. London: Chapman & Hall; 2004.
33. Mejía ME, Igartúa BMF, Schmidt EE, Cabaret J. Multispecies and multiple anthelmintic resistance on cattle nematodes in a farm in Argentina: the beginning of high resistance? Vet Res. 2003;34:461-7.
34. Nielsen M, Vidyashankar A, Hanlon B, Diao G, Petersen S, Kaplan R. Hierarchical model for evaluating pyrantel efficacy against strongyle parasites in horses. Vet Parasitol. 2013;197:614-22.
35. Vidyashankar A, Kaplan R, Chan S. Statistical approach to measure the efficacy of anthelmintic treatment on horse farms. Parasitology. 2007;134:2027-39.
36. Levecke B, Anderson RM, Berkvens D, Charlier J, Devleesschauwer B, Speybroeck N. Mathematical inference in helminth egg counts in stool and its applications in mass drug administration programmes to control soil-transmitted helminthiases in public health. Adv Parasitol. 2015;87:193-247.
37. Bolker BM, Brooks ME, Clark CJ, Geange SW, Poulsen JR, Stevens MHH, et al. Generalized linear mixed models: a practical guide for ecology and evolution. Trends Ecol Evol. 2009;24:127-35.
38. Hanley JA, Negassa A, Edwardes MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157:364-75.
39. Andrews P. A summary of the efficacy of praziquantel against schistosomes in animal experiments and notes on its mode of action. Arzneimittelforschung. 1981;31:538-41.
40. Anayi S, Al-Nasiri N. Acute mesenteric ischaemia caused by Schistosoma mansoni infection. Br Med J (Clin Res Ed). 1987;294:1197.
41. Smith J, Christie J. The pathology of human Schistosoma haematobium infections. In: Miller MJ, Love EJ, editors. Parasitic Diseases: Treatment and Control. Boca-Raton: CRC Press; 1989.
42. Silva IM, Thiengo R, Conceição MJ, Rey L, Lenzi HL, Pereira Filho E, et al. Therapeutic failure of praziquantel in the treatment of Schistosoma haematobium infection in Brazilians returning from Africa. Mem Inst Oswaldo Cruz. 2005;100:445-9.
43. Alonso D, Munoz J, Gascon J, Valls ME, Corachan M. Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am J Trop Med Hyg. 2006;74:342-4.
44. Booth M, Vounatsou P, N'Goran EK, Tanner M, Utzinger J. The influence if sampling effort and the performance of the Kato-Katz technique in diagnosing Schistosoma mansoni and hookworm co-infections in rural Côte d'Ivoire. Parasitology. 2003;127:525-31.
45. Lamberton PH, Kabatereine NB, Oguttu DW, Fenwick A, Webster JP. Sensitivity and specificity of multiple Kato-Katz thick smears and a circulating cathodic antigen test for Schistosoma mansoni diagnosis pre- and post-repeated-praziquantel treatment. PLoS Negl Trop Dis. 2014;8:e3139.
46. de Vlas SJ, Gryseels B. Underestimation of Schistosoma mansoni prevalences. Parasitol Today. 1992;8:274-7.
47. Ismail M, Metwally A, Farghaly A, Bruce J, Tao LF, Bennett JL. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg. 1996;55:214-8.
48. Danso-Appiah A, de Vlas SJ. Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol. 2002;18:125-9.
49. Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn NB, et al. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis. 2009;3, e504.
50. Jia TW, Melville S, Utzinger J, King CH, Zhou XN. Soil-transmitted helminth reinfection after drug treatment: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2012;6, e1621.
51. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008;21:659-67.
52. Mwinzi PNM, Kittur N, Ochola E, Copper PJ, Campbell Jr CH, King CH, et al. Additional evaluation of the point-of-contact circulating cathodic antigen assay for Schistosoma mansoni infection. Front Public Health. 2015;3:1-8.
53. Bustinduy AL. Pharmacokinetics and pharmacodynamics study of praziquantel in at 40 mg/kg or 60 mg/kg dosing in young Ugandan children infected with Schistosoma mansoni. In: The Burden of Schistosomiasis Morbidity in African Children: Validating Novel, low Cost and Scalable Detection Tools and Optimizing Praziquantel Treatment, PhD thesis. Amsterdam: University of Amsterdam; 2015.
54. Butterworth AE. Immunological aspects of human schistosomiasis. Br Med Bull. 1998;54:357-68.
55. Harnett W, Kusel J. Increased exposure of parasite antigens at the surface of adult male Schistosoma mansoni exposed to praziquantel in vitro. Parasitology. 1986;93:401-5.
56. Doenhoff MJ, Sabah AA, Fletcher C, Webbe G, Bain J. Evidence for an immune-dependent action of praziquantel on Schistosoma mansoni in mice. Trans R Soc Trop Med Hyg. 1987;81:947-51.
57. Brindley PJ, Sher A. Immunological involvement in the efficacy of praziquantel. Exp Parasitol. 1990;71:245-8.
58. Modha J, Lambertucci J, Doenhoff M, McLaren DJ. Immune dependence of schistosomicidal chemotherapy: an ultrastructural study of Schistosoma mansoni adult worms exposed to praziquantel and immune serum in vivo. Parasite Immunol. 1990;12:321-34.
59. King CH, Muchiri EM, Ouma JH. Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya. Emerg Infect Dis. 2000;6:585-94.
60. Woolhouse MEJ, Hagan P. Seeking the ghost of worms past. Nat Med. 1999;5:1225-7.
61. Black CL, Steinauer ML, Mwinzi PN, Evan Secor W, Karanja D, Colley DG. Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya. Trop Med Int Health. 2009;14:450-7.
62. Thiongo F, Mbugua G, Ouma J, Sturrock R. Efficacy of oxamniquine and praziquantel in school children from two Schistosoma mansoni endemic areas. East Afr Med J. 2002;79:29-33.
63. Fallon P, Hamilton J, Doenhoff M. Efficacy of treatment of murine Schistosoma mansoni infections with praziquantel and oxamniquine correlates with infection intensity: role of host antibody. Parasitology. 1995;111:59-66.
64. Montresor A. Cure rate is not a valid indicator for assessing drug efficacy and impact of preventive chemotherapy interventions against schistosomiasis and soil-transmitted helminthiasis. Trans R Soc Trop Med Hyg. 2011;105:361-3.